Tech Company Financing Transactions
Qnovia Funding Round
On 9/28/2022, Qnovia raised $17 million in Series A funding from Blue Ledge Capital, DG Ventures and Evolution VC Partners.
Transaction Overview
Company Name
Announced On
9/28/2022
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its NRT drug candidate through an IND submission with the FDA and begin human clinical trials in 2023.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2920 West Broad St #243
Richmond, VA 23230
USA
Richmond, VA 23230
USA
Phone
Website
Email Address
Overview
Qnovia is a platform medtech and pharmaceutical company whose mission is to help save lives. We've created a novel inhaled drug delivery platform to effectively deliver a broad range of pharmaceuticals. Our disruptive drug delivery technology is more than a medical device; it is a technology platform with multiple applications that have the potential to affect the lives of billions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Quigley
Chief Scientific Officer
Chris Cheng
Chief Technical Officer
Mario Danek
Co-Founder
Joe Walsh
Browse more venture capital transactions:
Prev: 9/28/2022: BioCircuit Technologies venture capital transaction
Next: 9/28/2022: Cionic venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs